Effect of Neoadjuvant Endocrine Therapy (Combined Androgen Blockade) on Normal Prostate and Pro static Carcinoma: A Randomized Study

American Journal of Surgical Pathology

Volumn 20, Issue 1, 1996, Pages 86-93

  Vaillancourt, Luc ^a   Têtu, Bernard ^a,b   Fradet, Yves ^a   Dupont, André ^b   Gomez, José ^b   Cusan, Leonello ^b   Suburu, E Raul ^b   Diamond, Pierre ^b   Candas, Bernard ^b   Labrie, Fernand ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Combination therapy; Combined androgen blockade; Flutamide; LHRH agonist; Lupron; Prostatic neoplasms; Pure antiandrogen; D Trp6, des Gly NH210 LHRH ethylamide

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MALE; MULTIMODALITY CANCER THERAPY; PREOPERATIVE TREATMENT; PROSTATE CARCINOMA; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANDROGEN ANTAGONISTS; CARCINOMA; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERENCE VALUES;

EID: 1542714492     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199601000-00010     Document Type: Article

References (34)

1. Armas OA, Aprikian AG, Melamed J, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994;18:979-91.
2. Basham KL, Austenfeld MS, Garcia FU. Quantitative effects of anti-androgen drugs on high grade prostatic intraepithelial neoplasia in radical prostatectomy specimens [Abstract 309]. Lab Invest 1993;68:55A.
3. Béland G, Elhilali M, Fradet Y, et al. Total androgen blockade versus castration in metastatic cancer of the prostate. In: Motta M, Serio M, eds. Hormonal therapy of prostatic diseases: basic and clinical aspects. Bussum: Medicom, 1988:302-11.
4. Bostwick DG. The pathology of early prostate cancer. CA Cancer J Clin 1989;39;376-93.
5. Catalona WJ, Avioli LV. Diagnosis, staging, and surgical treatment of prostatic carcinoma. Arch Intern Med 1987;147: 361-3.
6. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;313:419-24.
7. Denis L, Carneiro de Moura JL, Bono A, et al. Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). Urology 1993;42:119-29.
8. Fair WR, Aprikian AG, Reuter VE. Neoadjuvant hormonal manipulation. A strategy for chemoprevention trials. J Cell Biochem 1992;16:118-21.
9. Faure N, Labrie F, Lemay A, et al. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (GNRH) agonist in adult men. Fertil Steril 1982;37: 416-24.
10. Hellstrom M, Haggman M, Brandstedt S, et al. Histopathological changes in androgen-deprived localized prostatic cancer - a study in total prostatectomy specimens. Eur Urol 1993;24:461-5.
11. Huggins C, Hodges CV. Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-307.
12. Janknegt RA, Abbou CC, Bartoletti R, et al. Orchiectomy and Anandron (nilutamide) or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993;149:77-83.
13. Labrie F. Endocrine therapy for prostate cancer. Endocrinol Metab Clin North Am 1991;20:845-72.
14. Labrie F, Auclair C, Cusan L, Kelly PA, Pelletier G, Ferland L. Inhibitory effects of LHRH and its agonists on testicular gonadotropin receptors and spermatogenesis in the rat. In Hansson V, eds. 5th Annual Workshop on the Testis: endocrine approach to male contraception. Hvidovre, Denmark Scriptor Publisher APS, 1978;303-18.
15. Labrie F, Bélanger A, Cusan L, et al. Antifertility effects of LHRH agonists in the male. J Androl 1980;1:209-28.
16. Labrie F, Bélanger A, Dupont A, Luu-The V, Simard J, Labrie C. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 1993;16:487-504.
17. Labrie F, Bélanger A, Simard J, Labrie C, Dupont A. Combination therapy for prostate cancer: endocrine and biological basis of its choice as new standard first line therapy. Cancer 1993;71:1059-67.
18. Labrie F, Dupont A, Bélanger A, et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. J Clin Invest Med 1982; 5:267-75.
19. Labrie F, Dupont A, Bélanger A, et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 1985;123:833-41.
20. Labrie F, Dupont A, Cusan L, et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 1993;16:511-21.
21. Labrie F, Dupont A, Suburu R, et al. Serum prostatic specific antigen (PSA) as prescreening test for prostate cancer. J Urol 1992;147:846-52.
22. McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986;17:64-71.
23. Montironi R, Magi-Galluzzi C, Muzzonigro G, Prete E, Polito M, Fabris G. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. J Clin Pathol 1994;47:906-13.
24. Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 1991;68:821-8.
25. Ro JY, Grignon DJ, Troncoso P, Ayala AG. Intraluminal crystalloids in whole-organ sections of prostate. Prostate 1988;13:233-9.
26. Schmid HP, McNeal JE. An abbreviated standard procedure for accurate tumor volume estimation in prostate cancer. Am J Surg Pathol 1992;16:184-91.
27. Scott WW, Menon M, Walsh PL. Hormonal therapy of prostatic cancer. Cancer 1980;45:1929-36.
28. Smith DM, Murphy WM. Histologic changes in prostatic carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect): distinction from poor tumor differentiation. Cancer 1994;73:1472-7.
29. Soloway MS, Hachiya T, Civantos F, Murphy WM, Gomez CC, Ruiz HE. Androgen deprivation therapy prior to radical prostatectomy for T2b and T3 prostate cancer. Urology 1994;43:52-6.
30. Stamey TA, McNeal JE, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988;139:1235-41.
31. Têtu B, Srigley JR, Boivin JC, et al. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma: a histopathologic and immunohistochemical study. Am J Surg Pathol 1991;15: 111-20.
32. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. N Engl J Med 1984; 311:1281-6.
33. Van der Kwast Th H, Têtu B, Fradet Y, et al. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate, in press.
34. Walsh PC. Radical retropubic prostatectomy. In: Walsh PC, Beretik A, Stamey TA, Vaughan ED, eds. Campbell's urology 6th ed., Vol. 3, Philadelphia, WB Saunders, 1992:2865-86.